Women & HIV
Women & HIV
New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 March 2013 00:00
- Written by Anna Forbes
Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.
March 10 Is National Women and Girls HIV/AIDS Awareness Day
- Details
- Category: Women & HIV
- Published on Sunday, 10 March 2013 00:00
- Written by Liz Highleyman
Sunday is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), an annual opportunity to call attention to the burden of HIV and AIDS among women and girls worldwide.
According to the U.S. Centers for Disease Control and Prevention (CDC), women and adolescent girls (aged 13 and older) accounted for 21% of the nearly 50,000 new HIV diagnoses in the U.S. in 2011. The CDC estimates that just over 279,000 women and girls were living with HIV at the end of 2009 -- including 15% who are not aware they are infected.
AIDS 2012: Does Hormonal Contraception Increase the Risk of HIV Infection?
- Details
- Category: HIV Prevention
- Published on Friday, 27 July 2012 00:00
- Written by Gus Cairns
The 19th International AIDS Conference (AIDS 2012) heard further contradictory evidence this week on whether hormonal contraceptives, especially injectable ones, raise the risk to women of acquiring HIV and, if they already have HIV, of developing AIDS.
U.S. Conference on AIDS Underway this Week in Las Vegas
- Details
- Category: HIV Prevention
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
The U.S. Conference on AIDS (USCA), one of the major meetings focused on the domestic HIV/AIDS epidemic in the United States, is taking place this week in Las Vegas. Among the major themes are advances in HIV prevention, disparities in HIV epidemiology and access to care, implementation of the National HIV/AIDS Strategy, and how healthcare reform will affect people with HIV. Follow blog.Aids.gov for reports throughout the conference. 
Gilead Submits Applications for FDA Approval of Elvitegravir and Cobicistat
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 June 2012 00:00
- Written by Liz Highleyman
On June 27 Gilead Sciences announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of its new integrase inhibitor, elvitegravir, for use in combination antiretroviral therapy for treatment-experienced adults with HIV. The following day the company also requested approval of its novel boosting agent cobicistat.
Web Design and Development by